BREAKING CARDIOLOGY DISPATCH: Landmark Trial Confirms Vitamin K2 (MK-7) Halts Coronary Artery Calcification Progression

CHICAGO / LONDON — A revolutionary cardiovascular trial published in the autumn of 2026 has provided the definitive scientific answer to one of cardiology’s most pressing dilemmas: how to prevent calcium from accumulating in human heart arteries.

Figure 1: High-resolution vascular cross-section showing carboxylated Matrix Gla Protein actively scavenging calcium ions away from arterial collagen.

1. The Calcium Paradox: Why High Calcium Supplements Can Be Lethal

For decades, older adults were advised to swallow massive doses of synthetic calcium carbonate for bone density. Cardiologists now recognize the tragic downside of this guidance: without the enzymatic “traffic conductor” to direct that calcium into bone hydroxyapatite, excess calcium ends up depositing directly into coronary arteries, aortic valves, and kidneys.

2. The Critical MK-4 vs MK-7 Distinction

Not all Vitamin K2 is created equal:

• Menaquinone-4 (MK-4): Has a very short serum half-life of roughly 1 to 2 hours. It requires massive multi-milligram doses taken three times daily and rarely reaches peripheral vascular tissue in therapeutic quantities.
• Menaquinone-7 (MK-7): Derived from fermented natto, possesses a long lipophilic isoprenoid chain giving it a 72-hour human biological half-life. A single daily dose circulates continuously through the vascular tree, keeping Matrix Gla Protein activated around the clock.